Add Yahoo as a preferred source to see more of our stories on Google. While it’s not true that hidradenitis suppurativa is caused by poor hygiene, what you do in the shower can worsen flare-ups by ...
- New awareness campaign features authentic, often misunderstood, stories from people living with hidradenitis suppurativa (HS), highlighting the emotional and physical impact of the condition The ...
One of the best things you can do to make the day-to-day of hidradenitis suppurativa more manageable is to find a support group for people living with the same skin condition; the HS Foundation lists ...
A big part of living with the skin condition known as hidradenitis suppurativa (also known as HS or acne inversa) is paying attention to details in your day-to-day life: What factors seem to make new ...
Campaign offers resources and information about hidradenitis suppurativa (HS) and amplifies diverse patient voices and stories to reach people of all ages, races, and genders, including those most ...
A new study published in JMIR Dermatology shows that TikTok has become a major source of education and support for people with skin of color living with hidradenitis suppurativa—a chronic, painful ...
The Hearty Soul on MSN
Hidden dangers of hidradenitis suppurativa that everyone should know
Hidradenitis suppurativa (HS) is a chronic inflammatory HS skin disease that most people have never heard of – yet it affects ...
The Global Healthy Living Foundation (GHLF) announced today the launch of Your Interactive Patient Guide to Hidradenitis Suppurativa (HS), a groundbreaking resource designed to empower individuals ...
If you know anything about hidradenitis suppurativa, you can imagine how this chronic inflammatory skin condition can interfere not just with a person’s quality of life but also their sex life. Also ...
To investigate this further, Aileen Y. Chang, MD, and colleagues from the University of California did a cross-sectional study of patients in the dermatology clinic with newly diagnosed hidradenitis ...
Results showed a greater percentage of povorcitinib-treated patients achieved HiSCR50 compared with placebo at week 12. Topline data were announced from two pivotal phase 3 studies evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results